Daniel Catenacci, MD, University of Chicago Medicine

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Daniel Catenacci, MD, discusses recent updates in gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Daniel Catenacci, MD, and Sam Klempner, MD, conclude their discussion by examining emerging agents and biomarkers for the management of advanced gastric and esophagogastric junction cancers.

Experts in the management of gastric cancer discuss best practices for monitoring signs and symptoms of disease progression and explore factors to consider when switching therapies in later lines of treatment.

Gastric cancer specialists emphasize the importance of communication and education when selecting first-line treatment for patients with PD-L1-negative, HER2-positive disease.

Experts in gastrointestinal oncology review the challenges associated with molecular testing and the role of biomarker testing on disease management. 

Sam Klempner, MD, and Daniel Catenacci, MD, discuss the KEYNOTE-811 study of pembrolizumab plus trastuzumab in combination with chemotherapy in patients with HER2-positive disease.

Thought leaders in gastric and GEJ cancers review safety outcomes from the CHECKMATE649 trial presented at the 2021 ASCO annual meeting.

Key opinion leader in gastric cancer, Daniel Catenacci, MD, leads a discussion on the study design, patient population, and results from the CHECKMATE649 trial of nivolumab and chemotherapy in patients with gastric or GEJ cancers.

Daniel Catenacci, MD, and Sam Klempner, MD, consider the overall impact of recently approved immunotherapy-based regimens for gastric and gastroesophageal junction cancers.

Experts in the management of gastric cancer provide a historical perspective on available treatment options.

Daniel Catenacci, MD, discusses the challenges of developing novel therapies in gastroesophageal adenocarcinoma.

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.